Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 3, 2016-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension

By Okrucka A.   Pechan J.   Lova H. K Ratochvi  

Platelets, Vol. 9, Iss. 1, 1998-01 ,pp. : 63-67

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin-converting enzyme (ACE) inhibitor therapy after myocardial infarction in relation to left ventricular function

By Reikvam Aasmund   Kvan Elena   Landmark Knud   Aursnes Ivar  

Scandinavian Cardiovascular Journal, Vol. 37, Iss. 3, 2003-01 ,pp. : 130-134

Informa Healthcare

Access to resources Recommend Favorite

Aspirin, beta-blocker and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction

By Berger A.K.   Duval S.   Krumholz H.M.  

ACC Current Journal Review, Vol. 12, Iss. 5, 2003-09 ,pp. : 17-17

Elsevier

Access to resources Recommend Favorite

Letter to the Editor 'Effects of the angiotensin-converting enzyme inhibitor perindopril on endothelial and platelet function in essential hypertension'

By Jagroop I. A.   Papadakis J. A.   Mikhailidis D. P.  

Platelets, Vol. 9, Iss. 6, 1998-12 ,pp. : 395-396

Informa Healthcare

Access to resources Recommend Favorite